A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies
Coxsackievirus A6 (CV-A6) is one of pathogens causing hand, foot and mouth disease (HFMD) and becomes a new challenge to HFMD control. In this study, we first built a single-round pseudovirus infection system for CV-A6, and then developed a pseudovirus luciferase assay (PVLA) for anti-CV-A6 neutrali...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1504540 |
| _version_ | 1797677430175956992 |
|---|---|
| author | Yao Su Pan Chen Fan Gao Lianlian Bian Shiyang Sun Fangyu Dong Yalin Hu Qunying Mao Wei Jiang Xing Wu Zhenglun Liang |
| author_facet | Yao Su Pan Chen Fan Gao Lianlian Bian Shiyang Sun Fangyu Dong Yalin Hu Qunying Mao Wei Jiang Xing Wu Zhenglun Liang |
| author_sort | Yao Su |
| collection | DOAJ |
| description | Coxsackievirus A6 (CV-A6) is one of pathogens causing hand, foot and mouth disease (HFMD) and becomes a new challenge to HFMD control. In this study, we first built a single-round pseudovirus infection system for CV-A6, and then developed a pseudovirus luciferase assay (PVLA) for anti-CV-A6 neutralizing antibody (NtAb) quantification. Since cytopahtic effect (CPE) is considered as the gold standard test for anti-enterovirus NtAb detection, a comparison study has been performed using 318 clinical serum samples, as measured both by PVLA and CPE. The sensitivity and specificity of PVLA was 94.9% (95% CI between 90.8–97.5%) and 92.7% (95% CI between 86.6–96.6%), respectively. Statistical analysis revealed that PVLA and CPE were highly correlated (spearman r = 0.931, P < 0.0001) and in good agreement (94.0%, 95% CI between 90.8–96.4%), showing that PVLA could be used as a surrogate assay for anti-CV-A6 NtAb detection and served as a valuable tool for CV-A6 vaccine evaluation and CV-A6 epidemiological surveillance. |
| first_indexed | 2024-03-11T22:45:06Z |
| format | Article |
| id | doaj.art-abe62010f45b44758e757cb88e597f0a |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:45:06Z |
| publishDate | 2018-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-abe62010f45b44758e757cb88e597f0a2023-09-22T08:38:23ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2018-12-0114123034304010.1080/21645515.2018.15045401504540A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodiesYao Su0Pan Chen1Fan Gao2Lianlian Bian3Shiyang Sun4Fangyu Dong5Yalin Hu6Qunying Mao7Wei Jiang8Xing Wu9Zhenglun Liang10National Institute for Food and Drug ControlNational Institute of Biological SciencesNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlHualan Biological Engineering IncNational Institute for Food and Drug ControlChangchun Institute of Biological Products Co. LtdNational Institute for Food and Drug ControlNational Institute for Food and Drug ControlCoxsackievirus A6 (CV-A6) is one of pathogens causing hand, foot and mouth disease (HFMD) and becomes a new challenge to HFMD control. In this study, we first built a single-round pseudovirus infection system for CV-A6, and then developed a pseudovirus luciferase assay (PVLA) for anti-CV-A6 neutralizing antibody (NtAb) quantification. Since cytopahtic effect (CPE) is considered as the gold standard test for anti-enterovirus NtAb detection, a comparison study has been performed using 318 clinical serum samples, as measured both by PVLA and CPE. The sensitivity and specificity of PVLA was 94.9% (95% CI between 90.8–97.5%) and 92.7% (95% CI between 86.6–96.6%), respectively. Statistical analysis revealed that PVLA and CPE were highly correlated (spearman r = 0.931, P < 0.0001) and in good agreement (94.0%, 95% CI between 90.8–96.4%), showing that PVLA could be used as a surrogate assay for anti-CV-A6 NtAb detection and served as a valuable tool for CV-A6 vaccine evaluation and CV-A6 epidemiological surveillance.http://dx.doi.org/10.1080/21645515.2018.1504540coxsackievirus a6pseudovirusneutralizing antibodypseudovirus luciferase assay |
| spellingShingle | Yao Su Pan Chen Fan Gao Lianlian Bian Shiyang Sun Fangyu Dong Yalin Hu Qunying Mao Wei Jiang Xing Wu Zhenglun Liang A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies Human Vaccines & Immunotherapeutics coxsackievirus a6 pseudovirus neutralizing antibody pseudovirus luciferase assay |
| title | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| title_full | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| title_fullStr | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| title_full_unstemmed | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| title_short | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| title_sort | surrogate assay for measuring coxsackievirus a6 neutralizing antibodies |
| topic | coxsackievirus a6 pseudovirus neutralizing antibody pseudovirus luciferase assay |
| url | http://dx.doi.org/10.1080/21645515.2018.1504540 |
| work_keys_str_mv | AT yaosu asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT panchen asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT fangao asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT lianlianbian asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT shiyangsun asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT fangyudong asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT yalinhu asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT qunyingmao asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT weijiang asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT xingwu asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT zhenglunliang asurrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT yaosu surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT panchen surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT fangao surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT lianlianbian surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT shiyangsun surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT fangyudong surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT yalinhu surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT qunyingmao surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT weijiang surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT xingwu surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies AT zhenglunliang surrogateassayformeasuringcoxsackievirusa6neutralizingantibodies |